


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula (I)



wherein

R is halogen, C<sub>1-4</sub> alkyl, cyano, C<sub>1-4</sub> alkoxy, trifluoromethyl or trifluoromethoxy;

R<sub>1</sub> is a 4, 5 or 6 membered heterocyclic group, wherein the 4, 5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from (CH<sub>2</sub>)<sub>p</sub>R<sub>6</sub>, wherein p is zero or an integer from 1 to 4 and R<sub>6</sub> is selected from:

halogen,

C<sub>1-4</sub>alkoxy,

C<sub>1-4</sub>alkyl,

C<sub>3-7</sub>cycloalkyl,

C<sub>1-4</sub> alkyl optionally substituted by halogen, cyano or C<sub>1-4</sub> alkoxy,

hydroxy,

cyano,

nitro,

trifluoromethyl,

carboxy,

NH(C<sub>1-4</sub> alkyl),

$N(C_{1-4} \text{ alkyl})_2$   
 $NH(C_{3-7} \text{ cycloalkyl}),$   
 $N(C_{1-4} \text{ alkyl})(C_{3-7} \text{ cycloalkyl});$   
 $NH(C_{1-4} \text{ alkyl}OC_{1-4} \text{ alkoxy}),$   
 $OC(O)NR_7R_8,$   
 $NR_8C(O)R_7$  or  
 $C(O)NR_7R_8;$

$R_2$  is hydrogen, or  $C_{1-4}$  alkyl ;

$R_3$  and  $R_4$  independently are hydrogen,  $C_{1-4}$  alkyl or  $R_3$  together with  $R_4$  and the carbon to which they are bonded is  $C_{3-7}$  cycloalkyl;

$R_5$  is trifluoromethyl,  $S(O)_qC_{1-4} \text{ alkyl}$ ,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, trifluoromethoxy, halogen or cyano;

$R_7$  and  $R_8$  independently are hydrogen,  $C_{1-4}$  alkyl or  $C_{3-7}$  cycloalkyl;

$L$  is a single or a double bond;

$n$  is an integer from 1 to 3;

$m$  is zero or an integer from 1 to 3;

$q$  is zero or an integer from 1 to 2;

provided that

~~a) when  $L$  is a double bond,  $R_1$  is not an optionally substituted 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms;~~

[[b]] a) the group  $R_1$  is linked to the carbon atom shown as \* via a carbon atom;

and

[[c]] b) when the heteroatom contained in the group  $R_1$  is substituted,  $p$  is not zero;

or a pharmaceutically acceptable salt thereof.

2. (Previously Presented) A compound as claimed in claim 1 wherein  $R$  is halogen or  $C_{1-4}$  alkyl and  $n$  is an integer from 1 to 2.

3. (Previously Presented) A compound as claimed in claim 1 wherein R<sub>5</sub> is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is an integer from 1 to 2.
4. (Cancelled)
5. (Currently Amended) A compound as claimed in claim 1 wherein R is halogen or C<sub>1-4</sub> alkyl and n is an integer from 1 to 2; ~~R<sub>1</sub> is piperidyl, 2-morpholinyl, 1,2,3,6-tetrahydro-4-pyridinyl, pyridyl or pyrrolidinyl and wherein R<sub>1</sub> is optionally substituted by one or two groups selected from halogen, C<sub>1-4</sub> alkyl or ethylC<sub>1-4</sub> alkoxy; R<sub>2</sub> and R<sub>3</sub> are independently hydrogen or methyl; R<sub>4</sub> is hydrogen, methyl or together with R<sub>3</sub> is cyclopropyl and R<sub>5</sub> is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is preferably an integer from 1 to 2.~~
6. (Cancelled)
7. (Currently Amended) A compound selected from  
*N*-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide(diastereoisomer 1);  
*N*-{(1*S*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide (diastereoisomer 2);  
*N*-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide (diastereoisomer 1);  
*N*-[(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide (enantiomer 2);  
*N*-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-fluorophenyl)-3-(3-fluoro-3-piperidinyl)-*N*-methylpropionamide (diastereoisomer A);  
and pharmaceutically acceptable salts and solvates thereof.
- 8-11. (Cancelled)

12. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more pharmaceutically acceptable carriers or excipients.
13. (Cancelled)
14. (Previously Presented) A compound as claimed in claim 1 wherein R is fluorine or chlorine or methyl and n is an integer from 1 to 2.
15. (Currently Amended) A compound as claimed in claim 1 wherein R is fluorine or chlorine or methyl and n is an integer from 1 to 2; ~~R<sub>1</sub> is piperidyl, 2-morpholinyl, 1,2,3,6-tetrahydro-4-pyridinyl, pyridyl or pyrrolidinyl and wherein R<sub>1</sub> is optionally substituted by one or two groups selected from fluorine, methyl or ethyl~~ C<sub>1-4</sub> alkoxy; R<sub>2</sub> and R<sub>3</sub> are independently hydrogen or methyl; R<sub>4</sub> is hydrogen, methyl or together with R<sub>3</sub> is cyclopropyl and R<sub>5</sub> is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is preferably an integer from 1 to 2.
- 16-20. (Cancelled)